FRM
RGLS

Fox Run Management’s Regulus Therapeutics RGLS Stock Holding History

Fox Run Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-276
Closed -$96K – 653
2016
Q2 		$96K Buy
+276
New +$198K 0.05% 506
2016
Q1 		– Sell
-133
Closed -$140K – 531
2015
Q4 		$140K Buy
+133
New +$133K 0.11% 340

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fox Run Management's RGLS Position: Q3 2016 in Review

Fox Run Management sold out of Regulus Therapeutics (RGLS) in Q3 2016, closing a stake of 276 shares — an estimated $96K sold.

Fox Run Management first reported a position in RGLS in Q4 2015 and held it in 2 quarters. The position peaked at $140K in Q4 2015. 83 funds tracked by Wall St. Rank hold RGLS as of Q3 2016.

  • Fox Run Management reported no remaining Regulus Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Fox Run Management sold 276 Regulus Therapeutics shares in Q3 2016, an estimated $96K.
  • Fox Run Management first reported a position in Regulus Therapeutics in Q4 2015 and held it in 2 quarters.
  • Fox Run Management's Regulus Therapeutics position peaked at $140K in Q4 2015.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2016.

Based on Fox Run Management's 13F filing for Q3 2016, filed 12 Oct 2016.